Literature DB >> 20463087

Commentary: chronic lymphocytic leukemia--the price of progress.

Tait D Shanafelt1, Heidi Gunderson, Timothy G Call.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20463087      PMCID： PMC3227992          DOI： 10.1634/theoncologist.2010-0090

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  4 in total

1.  Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.

Authors:  Neil E Kay; Susan M Geyer; Timothy G Call; Tait D Shanafelt; Clive S Zent; Diane F Jelinek; Renee Tschumper; Nancy D Bone; Gordon W Dewald; Thomas S Lin; Nyla A Heerema; Lisa Smith; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2006-09-28       Impact factor: 22.113

2.  Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Authors:  Michael J Keating; Susan O'Brien; Maher Albitar; Susan Lerner; William Plunkett; Francis Giles; Michael Andreeff; Jorge Cortes; Stefan Faderl; Deborah Thomas; Charles Koller; William Wierda; Michelle A Detry; Alice Lynn; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2005-03-14       Impact factor: 44.544

3.  Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.

Authors:  Kenneth A Foon; Michael Boyiadzis; Stephanie R Land; Stanley Marks; Anastasios Raptis; Louis Pietragallo; Dennis Meisner; Andrew Laman; Mathew Sulecki; Allyson Butchko; Patricia Schaefer; Diana Lenzer; Ahmad Tarhini
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

4.  Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

Authors:  John C Byrd; Bercedis L Peterson; Vicki A Morrison; Kathleen Park; Robert Jacobson; Eva Hoke; James W Vardiman; Kanti Rai; Charles A Schiffer; Richard A Larson
Journal:  Blood       Date:  2002-07-05       Impact factor: 22.113
  4 in total
  6 in total

1.  Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Authors:  Tait D Shanafelt; Neil E Kay; Kari G Rabe; David J Inwards; Clive S Zent; Jose F Leis; Susan M Schwager; Carrie A Thompson; Deborah A Bowen; Thomas E Witzig; Susan L Slager; Timothy G Call
Journal:  Cancer       Date:  2011-08-26       Impact factor: 6.860

Review 2.  Model-based cost-effectiveness analyses for the treatment of chronic lymphocytic leukaemia: a review of methods to model disease outcomes and estimate utility.

Authors:  Kevin Marsh; Peng Xu; Panagiotis Orfanos; James Gordon; Ingolf Griebsch
Journal:  Pharmacoeconomics       Date:  2014-10       Impact factor: 4.981

Review 3.  Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia-the Burden of Novelty.

Authors:  Talal Hilal; Jeffrey A Betcher; Jose F Leis
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

Review 4.  Exploring Big Data in Hematological Malignancies: Challenges and Opportunities.

Authors:  Gustavo F Westin; Ajoy L Dias; Ronald S Go
Journal:  Curr Hematol Malig Rep       Date:  2016-08       Impact factor: 3.952

Review 5.  Nanotechnology applications in hematological malignancies (Review).

Authors:  Ahmed Samir; Basma M Elgamal; Hala Gabr; Hatem E Sabaawy
Journal:  Oncol Rep       Date:  2015-07-02       Impact factor: 3.906

6.  Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis.

Authors:  Thitima Kongnakorn; James A Sterchele; Christopher G Salvador; Denis Getsios; Mkaya Mwamburi
Journal:  Clinicoecon Outcomes Res       Date:  2014-04-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.